We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biological Markers Evaluated for Early Cervical Cancer Diagnosis

By LabMedica International staff writers
Posted on 27 Jun 2013
A method for the early diagnosis and prognosis of cervical cancer has been investigated which may lead to potential gene therapy biological targets. More...


The expression of the anti-oncogene phosphatase and tensin (PTEN) homologue and survivin in the progression of cervical neoplasia has been elucidated based on clinic-pathological features in squamous cell carcinoma of the uterine cervix.

Scientists at the Yangzhou University Medical College (China) enrolled for a study 20 patients with cervical ectropion and squamous metaplasia, 30 with cervical intraepithelial neoplasia, and 49 with cervical squamous cell carcinoma between January 2010 and August 2011. Normal cervical epithelium from 10 people served as the control. Immunohistochemical staining was performed to detect PTEN and survivin expression in each group using a streptavidin kit (Zhongshan Golden Bridge Biotechnology, Beijing, China).

The investigators found that PTEN expression progressively decreased with the continuum from normal epithelium to squamous cell carcinoma, whereas survivin expression progressively increased. Furthermore, positive PTEN immunostaining was associated with clinical stage and tumor size. The level of PTEN expression in the metastatic pelvic lymph node group was significantly lower compared with the nonmetastatic pelvic lymph node group. Positive survivin immunostaining was associated with clinical stage and tumor size. Survivin-positive expression in the metastatic pelvic lymph node group was significantly higher compared with the nonmetastatic pelvic lymph node group.

The PTEN gene acts as a tumor suppressor gene through the action of its phosphatase protein product, while survivin is a protein encoded by the antiapoptotic gene baculoviral inhibitor of apoptosis repeat containing 5 (BIRC5). The authors concluded that positive expression levels of PTEN and survivin provide potential evaluation indices for early diagnosis and prognosis of uterine cervical cancer, and these biomarkers are also potentially promising therapeutic targets. The study was published in the June 2013 online edition of the journal the British Journal of Biomedical Science.

Related Links:

Yangzhou University Medical College
Zhongshan Golden Bridge Biotechnology



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.